Erschienen in:
01.09.2022 | Review Article
Ki 67: a Promising Prognostic Marker in Early Breast Cancer—a Review Article
verfasst von:
Dhanya Mary Louis, Lakshmi Malavika Nair, Archana George Vallonthaiel, M. P. Narmadha, D. K. Vijaykumar
Erschienen in:
Indian Journal of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Abstract
Ki67 index is considered to be a reliable indicator of the proliferative activity of breast cancer. Additionally, the Ki67 proliferative marker may play a role in assessing response to systemic therapeutic strategies and can act as a prognostic biomarker. But its limited reproducibility which stems from a lack of standardization of procedures, inter-observer variability, and preanalytical and analytical variabilities all have hampered the use of the Ki67 index in clinical practice. Currently, clinical trials have been evaluating Ki67 as a predictive marker for needing adjuvant chemotherapy in luminal early breast cancer patients receiving neoadjuvant endocrine therapy. But the inconsistencies existing in the estimation of the Ki67 index limit the utility of Ki67 in standard clinical practice. The purpose of this review is to evaluate the benefits and drawbacks of utilizing Ki-67 in early-stage breast cancer to prognosticate the disease and predict the risk of recurrence.